ArticleVirology journal2026
The three-decade trajectory of hepatitis C burden among women of reproductive age in China: a retrospective and predictive study.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluates the changing burden of hepatitis C (HCV) among women of reproductive age (15-49 years) in China from 1990-2021 and forecasts trends to 2035.
methodsUsing data from the Global Burden of Disease 2021 study, we analyzed age-standardized rates (ASRs) for incidence, prevalence, mortality, and disability-adjusted life years (DALYs) related to acute and chronic HCV in this population. Statistical analyses included estimating annual percentage changes (EAPCs), applying Poisson-based age-period-cohort (APC) modeling to assess epidemiological drivers, and employing Bayesian APC modeling for future projections. Decomposition analysis was used to quantify contributions from population growth, aging, and epidemiological factors.
resultsFrom 1990 to 2021, all ASRs for HCV among women of reproductive age in China showed significant declines, with rates of decrease surpassing global averages. Despite this progress, China remained a high-burden country for this group in 2021, with a large reservoir of chronic HCV cases. A notable rebound in the incidence of chronic HCV occurred after 2010. Epidemiological trends displayed clear age stratification: the most substantial improvements were observed in younger cohorts (aged 15-24 years), while older groups (aged 45-49 years) experienced slower declines or recent rebounds in incidence. Decomposition analysis indicated that the reduction in disease burden was primarily driven by epidemiological improvements (e.g., in prevention and treatment), which successfully offset the adverse effects of population growth. This pattern contrasts with the global trend, where increasing burden is largely attributed to demographic factors. Projections suggest a continued decline in ASRs and case numbers through 2035, although the rate of decline is expected to slow.
conclusionsHistorical HCV control measures for women of reproductive age in China have been effective, as evidenced by steep declines in mortality and DALYs. However, persistent challenges include a substantial existing patient pool and a resurgent incidence, particularly among older individuals within this demographic. This study precisely quantifies a successful epidemiological transition and identifies a shift in risk profiles, underscoring the continued need for sustained, age-tailored public health interventions to achieve HCV elimination goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.